Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Melanoma 9Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Skin Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Klatskin Tumor 1Glioma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Eye Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Sunitinib 5ripretinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Biopsy 2regorafenib 1binimetinib 1Temozolomide 1TAS-116 1Sorafenib 1Rogaratinib 1Poly(ADP-ribose) Polymerase Inhibitors 1Nivolumab 1Midazolam 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastrointestinal Stromal Tumors × binimetinib × Clear all
NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
75 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡